1AD 5.00% 2.1¢ adalta limited

Ann: AD-214 pathway to IPF efficacy studies, page-54

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,543 Posts.
    lightbulb Created with Sketch. 511
    This is a real blow-out in the timeline. I know they are saying that they hope to be at phase II at roughly the same time as previously planned. But we were initially going to have phase I efficacy data to at least give us an idea of whether it worked in IPF in humans.

    Now it's 3-4 years before we have any efficacy data.
 
watchlist Created with Sketch. Add 1AD (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
0.001(5.00%)
Mkt cap ! $12.73M
Open High Low Value Volume
2.0¢ 2.1¢ 2.0¢ $21.61K 1.058M

Buyers (Bids)

No. Vol. Price($)
1 550000 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 629346 2
View Market Depth
Last trade - 15.40pm 11/10/2024 (20 minute delay) ?
1AD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.